

1
2 **PHARMACOPOEIAL DISCUSSION GROUP**

3
4 **CORRECTION 2**

5 CODE: ... E25

6 **NAME: ...Magnesium Stearate**

7 (Correction of the sign-off document ... signed 11 November 2008)

8
9
10
11
12 **Item to be corrected: ...**

13 Limit of Sulfate: Compare the turbidity, if any, with that produced in a solution containing
14 3.0 mL of 0.020 M sulphuric acid (1.0%).

15
16 **European Pharmacopoeia**

17
18 Signature

19 
20

Name


C. Vielle

Date

06/06/2012

21 **Japanese Pharmacopoeia**

22
23 Signature

24 
25

Name

Toru KAWANISHI


Date

6/6/2012

for Haruo Akagawa

26 **United States Pharmacopoeia**

27
28 Signature

29 
30

Name

PRAVEEN TYAGI

Date

June 6, 2012

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

PHARMACOPOEIAL DISCUSSION GROUP

CORRECTION


CODE: E13

NAME: Cellulose Acetate Phthalate (Rev.1, Corr.1)
(Correction of the sign-off document signed 09 November 2010)


Item to be corrected:

1. IDENTIFICATION B: add the statement that "Record the infrared absorption spectrum of cellulose acetate phthalate and compare with the Reference Spectrum or the spectrum obtained with the Reference Standard: the transmission minima correspond in position and relative size." in this attribute.

European Pharmacopoeia

Signature  Name C. Viella Date 06/06/12

Japanese Pharmacopoeia

Signature  Name Toru KAWANISHI Date 6/6/2012
for Haruo Akagawa

United States Pharmacopeia

Signature  Name PRAVEEN TYLE Date June 6, 2012